The law firm Levi & Korsinsky, LLP has filed a class action lawsuit against Altimmune, Inc., a biopharmaceutical company, on behalf of investors who experienced losses due to alleged securities fraud. The suit covers the period from August 10, 2023, to June 25, 2025.
The complaint alleges that Altimmune misled investors leading up to the release of topline results from the IMPACT Phase 2b clinical trial of Pemvidutide for the treatment of metabolic-associated fatty liver disease (MASH). The company’s June 26, 2025, announcement revealed that the trial failed to achieve statistical significance in its primary endpoint, fibrosis reduction.
While the trial showed a positive trend in fibrosis improvement, a higher-than-expected placebo response prevented the achievement of statistical significance. Altimmune attributed the results to the Phase 2 nature of the trial and expressed hopes for improved outcomes in a future Phase 3 trial.
Following this announcement, Altimmune’s stock price plummeted. The stock closed at $7.71 per share on June 25, 2025, but fell to $3.61 per share the following day, a drop of over 50%.
Levi & Korsinsky is seeking to recover losses for investors affected by the stock price decline. The deadline for investors to request appointment as lead plaintiff is October 6, 2025. Participation in the lawsuit does not require serving as lead plaintiff.
The firm emphasizes that there is no cost or obligation for class members to participate, and they may be eligible for compensation without incurring any out-of-pocket expenses.
Levi & Korsinsky highlights its extensive experience in securities litigation and its track record of success in securing significant recoveries for investors. The firm has a large team dedicated to serving its clients and has consistently ranked among the top securities litigation firms in the United States. Investors are encouraged to contact the firm to learn more about their options.
Related
